MK2461 in Patients With Advanced Cancer (2461-001)(COMPLETED)
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a first-in-human trial to establish the safety, tolerability, Recommended Phase II
Dose (RP2D), pharmacodynamic, and clinical activity of MK2461.